News | Computed Tomography (CT) | April 27, 2022

Choice of oral contrast agent and adequacy of preparation impact detection of intra-abdominal nonsolid malignant deposits on CT, although NPV remains suboptimal

66-Year-Old Man With Locally Advanced Pancreatic Cancer Undergoing Chemotherapy

66-Year-Old Man With Locally Advanced Pancreatic Cancer Undergoing Chemotherapy: (A) Axial image from contrast-enhanced CT using positive oral contrast material, performed to monitor treatment response. Examination clinically interpreted as not showing metastatic disease. Unblinded retrospective image review shows tiny omental nodule (arrow) near bowel loops. Adequacy of bowel filling with contrast material rated very good. Both blinded retrospective readers detected nodule. (B) Axial image from contrast-enhanced CT performed two months later shows slight increase in size of nodule (arrow) and several new nodules (arrowheads), confirming lesion as missed malignant deposit. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)


April 27, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), the selection of oral contrast agent and optimization of bowel preparation for oncologic computed tomography (CT) could help avoid potentially severe clinical consequences of missed malignant deposits.

“CT has suboptimal NPV for malignant deposits in intraabdominal nonsolid organs,” wrote corresponding author Benjamin M. Yeh of the University of California, San Francisco. “Compared to neutral material, positive oral contrast material improves detection, particularly with adequate bowel filling.”

Yeh and team’s retrospective study included 265 patients (133 men, 132 women; median age, 61 years) who underwent an abdominopelvic CT examination where the report did not suggest presence of malignant deposits and subsequent CT examination within 6 months where the report indicated at least one unequivocal malignant deposit. Examinations used positive (iohexol; n=100) or neutral (water; n=165) oral agents. While reviewing images to assess visibility of deposits, a board-certified abdominal radiologist also assessed adequacy of bowel filling with oral contrast material.

NPV of CT for detection of malignant deposits in intraabdominal nonsolid organs was 65.8% for examinations using positive oral contrast material with adequate bowel filling, 45.2% for positive oral contrast material with inadequate bowel filling (p=.07), and 35.2% for neutral oral contrast material regardless of adequacy of bowel filling (p=.002).

“Results may differ when studying other types of contrast material regimens,” the authors of this AJR article noted, including barium-based, hyperosmolar iodine, sugar-alcohol neutral, or experimental dark oral agents.

For more information: www.arrs.org


Related Content

News | Endoscopes

Oct. 22, 2025 — Fujifilm Healthcare Americas Corp. has launched its advanced endoscopy platform, the ELUXEO 8000 ...

Time October 23, 2025
arrow
News | X-Ray

Oct. 22, 2025 — Imaging technology company Adaptix has begun live imaging trials as part of a research program at the ...

Time October 22, 2025
arrow
News | Contrast Media

Oct. 21, 2025 — Subtle Medical, Inc., a provider of AI-powered medical imaging solutions, has announced positive ...

Time October 21, 2025
arrow
News | Radiology Imaging | UC San Diego Health

Oct. 16, 2025 — A strategic collaboration between UC San Diego Health and GE HealthCare will focus on bringing advanced ...

Time October 20, 2025
arrow
News | Artificial Intelligence

Oct. 20, 2025 — Viz.ai has launched of Viz Assist, a suite of autonomous AI agents that significantly enhance how care ...

Time October 20, 2025
arrow
News | Point-of-Care Ultrasound (POCUS)

Oct. 15, 2025 — GE HealthCare has announced the latest advancement in its Venue family of point-of-care ultrasound ...

Time October 16, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

September 24, 2025—According to the American Journal of Roentgenology (AJR), MRI can reliably identify lateral meniscal ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Oct. 01, 2025 – Nuclidium AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time October 02, 2025
arrow
News | Radiology Business | Harvey L. Neiman Health Policy Institute

Sept. 30, 2025 — A new study from the Harvey L. Neiman Health Policy Institute found that attrition (i.e., exit) from ...

Time October 02, 2025
arrow
News | Prostate Cancer

Sept. 30, 2025 – EDAP TMS's non-invasive, nonsurgical treatment option, Focal One Robotic HIFU, was featured on national ...

Time September 30, 2025
arrow
Subscribe Now